GXP

Typical Microbiology Concerns in an FDA Inspection – Part 3

Abstract

One is always concerned with trying to understand how to look good during an FDA inspection.  It can be difficult to predict what items will be of concern in the area of microbiology.  Part 1 of this series discussed microbiological concerns in the quality systems-based inspection.  Part 2 of the series discussed review of microbiology data and how FDA looks at the data.  This part discusses some of the regulatory concerns associated with reviewing a microbiological out-of-specification result.

Background

Since the issuance of the Barr Decision (USA, 2993) the term out-of-specification became a “household word” in pharmaceutical companies.  Prior to this time, FDA more often utilized the term Failure Investigation. (21CFR 211.192) Interpreting this decision for pharmaceutical analytical laboratories (Chemistry and Microbiology) was confusing for the immediate time following the decision’s issuance.   Many different consultants, who did not participate in the lawsuit, opined on what this meant for microbiology.  Quite a bit of conflicting information ensued.  Since that time, FDA issued industry guidance on the investigation of out-of-specification test results. (FDA, 2016)

This content is only available to IVT members.
Get help maintaining your knowledge . Read More!

If you are already a member and you do not have access to this article, upgrade your membership.
Need help? Read our FAQs.




Product Added Successfully

This product has been added to your account and you can access it from your dashboard. As a member, you are entitled to a total of 0 products.

Do you want access to more of our products? Upgrade your membership now!

Your Product count is over the limit

Do you want access to more of our products? Upgrade your membership now!

Product added to cart successfully.

You can continue shopping or proceed to checkout.